Detection of IgG antibody during the follow-up in patients with COVID-19 infection

Liu, Jiao; Guo, Jun; Xu, Qianghong; Cai, Guolong; Chen, Dechang; Shen, Yanfei

doi:10.1186/s13054-020-03138-4

Cited by 14 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the key role of IgG in modulating the immune response, further efforts in developing vaccines and preventing reinfection are dependent on a better understanding of IgG changes in patients who have recovered from COVID-19 infection. Liu et al tested 484 patients for SARS-CoV-2 IgG antibodies at 100 days after symptom onset and noted that 18% were tested negative [30]. In our study, the level of SARS-CoV-2 IgG rose signi cantly in patients at 3 months of follow-up (Group A and B) ( Fig.…”

Section: Arterial Blood Gas Analysis At Follow-upsupporting

confidence: 53%

Pulmonary Dysfunction in Patients Recovered from COVID-19 Pneumonia: A 6-Month Follow-up Study

Meng

Kang

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

Objectives: This study investigates the clinical features and pulmonary functions of COVID-19 pneumonia survivors at 3 or 6 months after diagnosis in the Heilongjiang Province, China.Methods: Forty-six patients with COVID-19 pneumonia diagnosed since February 2020 were enrolled in this study for follow-up in July 2020. These patients were categorized into three groups: Group A (n=24) and Group B (n=11) who were diagnosed with moderate or severe pneumonia and followed up at three months after diagnosis; Group C (n=11) who were diagnosed with severe pneumonia and followed up at six months after diagnosis. Data on pulmonary function, arterial blood gas analysis, chest CT, blood test, antibody test, and health-related quality of life during hospitalization and at the follow-up visits were collected and analyzed. Results: Abnormal PO2 (A-a) was more prevalent in severe cases (Group B and C) than in moderate cases (Group A). Pulmonary dysfunction was common in this cohort. Abnormal CT scores of severe cases (Group B and C) were significantly higher than that of moderate cases (Group A). During the follow-up, lung abnormalities gradually resolved in the first 3 months (Group A and B), however, further resolution was not significant from 3 months to 6 months (Group B and C). Conclusion: Although pulmonary interstitial changes due to COVID-19 pneumonia gradually reverse over time, pulmonary dysfunction is common and appears to persist at least up to 6 months in patients recovered from COVID-19 pneumonia.

show abstract

Section: Arterial Blood Gas Analysis At Follow-upsupporting

confidence: 53%

Pulmonary Dysfunction in Patients Recovered from COVID-19 Pneumonia: A 6-Month Follow-up Study

Meng

Kang

Gao

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Theodore Roosevelt carrier during a SARS-CoV-2 outbreak; this study had high risk of bias due to low participation (27% of eligible participants were included in the sample), differences in the age and racial distribution of participants compared with nonparticipants, and use of participant self-report for RT-PCR and serology test results ( 49 ). Among cross-sectional and cohort studies with high risk of bias, the most serious methodological issues were unclear patient selection methods (that is, whether selection was random or consecutive) and lack of adjustment for confounding factors, like age, that could influence subgroup comparisons ( 16 , 18 , 24 , 40 , 42 , 45 , 51 , 54 , 57 , 66 , 68 , 74 , 76 , 77 , 79 ). In the immunoassay validation studies, inadequate reporting of patient selection methods and unclear or inconsistent criteria for interpreting immunoassay results meant that we could not rule out high risk of bias and limited the clinical applicability of results ( 14 , 15 , 22 , 25 , 26 , 32 , 33 , 37 , 43 , 44 , 48 , 56 , 64 , 65 , 69 , 71 , 72 ).…”

Section: Resultsmentioning

confidence: 99%

Antibody Response After SARS-CoV-2 Infection and Implications for Immunity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…(2) 45 cross-sectional or cohort studies [18][19][20][21][22][23]25,26,29,31,32,35,37,[39][40][41][42][43][44]47,48,[51][52][53][54][55][56][58][59][60][61][62][63][64][67][68][69]71,[74][75][76][77][78][79][80] characterizing the antibody response (i.e., antibody types, levels, and duration) among adults with SARS-CoV-2 infection; and 317 studies validating the diagnostic performance of one or more immunoassays. 16,17,24,27,…”

Section: Study Characteristicsmentioning

confidence: 99%

“…50 Among cross-sectional and cohort studies with high risk of bias, the most serious methodologic issues were unclear patient selection methods (i.e., whether selection was random or consecutive) and lack of adjustment for confounding factors, like age, that could influence subgroup comparisons. 18,20,41,43,47,52,55,58,67,69,77,78,80 In the immunoassay validation studies, inadequate reporting of patient selection methods and unclear or inconsistent criteria for interpreting immunoassay results meant we could not rule out high risk of bias and limited the clinical applicability of results. 16,17,24,27,28,33,34,38,45,46,49,57,65,66,70,72,73 Abbreviations: IgM/G/A = immunoglobulin M/G/A; Nab = neutralizing antibody; RT-PCR+ = reverse transcription polymerase chain reaction positive result; RT-PCR = reverse transcription polymerase chain reaction.…”

Section: Study Characteristicsmentioning

confidence: 99%

Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review

Mackey

Arkhipova-Jenkins

Armstrong

et al. 2021

View full text Add to dashboard Cite

 Evidence suggests that the majority of adults develop detectable levels of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies following infection with SARS-CoV-2 (moderate strength of evidence* [SoE]).  IgM levels peak approximately 20 days after symptom onset or RT-PCR diagnosis and subsequently decline. IgG levels peak approximately 25 days after symptom onset or RT-PCR diagnosis and may remain detectable for at least 120 days (moderate SoE*).  Almost all adults develop neutralizing antibodies in response to SARS-CoV-2 infection, and these antibodies may remain detectable for at least 152 days (low SoE*).  A small percentage of people do not develop antibodies in response to SARS-CoV-2 infection for reasons that are largely unclear but may be related to less severe disease or absence of symptoms.  Antibody prevalence does not appear to vary by age or sex, but older age may be associated with higher antibody levels (low SoE*). Non-White race may be associated with higher antibody prevalence and levels (low SoE*). COVID-19 severity and presence of symptoms may also be associated with higher antibody prevalence or levels (low SoE*). More evidence is needed to draw stronger conclusions regarding how the antibody response varies by patient characteristics and disease factors.  Studies to date have not established the relationship between the development of antibodies after RT-PCR-diagnosed SARS-CoV-2 infection and the risk of reinfection. Studies based on index serologic testing suggest that the presence of antibodies is associated with a lower risk of a subsequent positive SARS-CoV-2 RT-PCR test.

show abstract

Detection of IgG antibody during the follow-up in patients with COVID-19 infection

Cited by 14 publications

References 4 publications

Pulmonary Dysfunction in Patients Recovered from COVID-19 Pneumonia: A 6-Month Follow-up Study

Pulmonary Dysfunction in Patients Recovered from COVID-19 Pneumonia: A 6-Month Follow-up Study

Antibody Response After SARS-CoV-2 Infection and Implications for Immunity

Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Rapid Living Review

Contact Info

Product

Resources

About